TENS

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Retrieved on: 
Wednesday, March 13, 2024
TENS, Fibromyalgia, Label, Patient, Contraindication, Sleep, Sale, Rehabilitation, Physical medicine and rehabilitation, Consultant, Pain

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

Key Points: 
  • WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
  • “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix.
  • In my practice, we have even had some patients report they were able to reduce pain with Quell Fibromyalgia that medications have never helped before."
  • The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109.

Tactical Rehabilitation, Inc. wins two Business Worldwide Magazines Corporate Excellence Awards

Retrieved on: 
Thursday, January 25, 2024
Patient, Sustainability, PTSD, Post-traumatic stress disorder, Health, Culture, TENS, CSR, Veteran, Love, 3D, Human, Chronic pain, Military personnel, Nursing, Depression

The company has now won two Business Worldwide Global Corporate Excellence Awards; Visionary Leadership in the Healthcare Business' & 'Corporate Social Responsibility (CSR) and Sustainability Champion'.

Key Points: 
  • The company has now won two Business Worldwide Global Corporate Excellence Awards; Visionary Leadership in the Healthcare Business' & 'Corporate Social Responsibility (CSR) and Sustainability Champion'.
  • In its 2023 round, the Global Corporate Excellence Awards continue to shine a spotlight on organisations and leaders who focus on relentless excellence in the business world.
  • By acknowledging these achievements on a global stage, these awards not only celebrate success but also encourage others to follow suit, fostering a culture of excellence that transcends borders and industries.
  • Over thirty years, Kevin MacRitchie has demonstrated impressive strengths in business turnaround and business structuring for rapid profitable growth.

Tactical Rehabilitation, Inc. wins two Business Worldwide Magazines Corporate Excellence Awards

Retrieved on: 
Thursday, January 25, 2024
Patient, Sustainability, PTSD, Post-traumatic stress disorder, Health, Culture, TENS, CSR, Veteran, Love, 3D, Human, Chronic pain, Military personnel, Nursing, Depression

The company has now won two Business Worldwide Global Corporate Excellence Awards; Visionary Leadership in the Healthcare Business' & 'Corporate Social Responsibility (CSR) and Sustainability Champion'.

Key Points: 
  • The company has now won two Business Worldwide Global Corporate Excellence Awards; Visionary Leadership in the Healthcare Business' & 'Corporate Social Responsibility (CSR) and Sustainability Champion'.
  • In its 2023 round, the Global Corporate Excellence Awards continue to shine a spotlight on organisations and leaders who focus on relentless excellence in the business world.
  • By acknowledging these achievements on a global stage, these awards not only celebrate success but also encourage others to follow suit, fostering a culture of excellence that transcends borders and industries.
  • Over thirty years, Kevin MacRitchie has demonstrated impressive strengths in business turnaround and business structuring for rapid profitable growth.

Enhancing Chiropractic Practices: A Comprehensive Guide to Essential Equipment

Retrieved on: 
Thursday, January 11, 2024
Table, Patient, Tendon, Spinal cord compression, Health, Multimedia, TENS, Ligament, Pain, Inflammation, Cryotherapy

DALLAS, Jan. 11, 2024 /PRNewswire-PRWeb/ -- In the realm of chiropractic care, success is not solely dependent on effective treatment and superior patient service; it also hinges on the strategic investment in cutting-edge equipment. As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.

Key Points: 
  • This comprehensive article highlights the crucial role of cutting-edge equipment in the success of chiropractic practices.
  • Notably, the article directs practitioners to ChiroEquip.com, a premier online destination offering a diverse array of essential tools from renowned industry brands, including Pivotal Health Solutions and Elite Chiropractic Tables.
  • As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.
  • For chiropractors seeking a comprehensive selection of equipment from renowned industry brands such as Pivotal Health Solutions and Elite Chiropractic Tables, www.ChiroEquip.com emerges as a premier online destination.

Brad Jacobs to Enter Building Products Distribution Industry

Retrieved on: 
Monday, December 11, 2023
Annual report, Comparison (grammar), Ecosystem, Failure, End, Risk, Sale, Acquisition, Robotics, B2B, United Rentals, HVAC, XPO, JPE, Water, Ageing, Weather, Growth, TENS, Investment, Automation, History, Communication, Security (finance)

GREENWICH, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- After a comprehensive year-long search, Brad Jacobs has announced his intention to create a market leader in building products distribution — an industry with approximately $800 billion in annual revenue between North America and Europe, according to industry estimates. The company will be called QXO, Inc.

Key Points: 
  • The company will be called QXO, Inc.
    “QXO’s strategy is to create a tech-forward leader in the building products distribution industry through accretive M&A and organic growth, including greenfield openings, with the goal of generating outsized stockholder value,” Jacobs said.
  • Distributors of building products offer materials, finished goods, value-added solutions and expertise to a broad range of customers across residential, nonresidential, industrial and infrastructure end-markets.
  • The building products distribution industry is highly fragmented, with approximately 7,000 distributors in North America and 13,000 in Europe, according to industry observers.
  • The industry has generated compound annual revenue growth of 7% over the last five years, based on industry data, and continues to benefit from powerful secular growth drivers for building products distribution in the residential, nonresidential and infrastructure sectors.

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Retrieved on: 
Tuesday, December 5, 2023
Peripheral neuropathy, Quality of life, The Journal of Pain, TENS, ASCO, FDA, Clinical trial, CIPN, NIH, Patient, Safety, RCT, Journal, Skin, Pharmaceutical industry

The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial.

Key Points: 
  • The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial.
  • A total of 142 subjects with CIPN were randomized to an active or sham Quell device for 6-weeks.
  • Duloxetine is the only treatment recommended for painful chronic CIPN in the current American Society of Clinical Oncology (ASCO) guidelines.
  • The use of Quell for chemotherapy induced peripheral neuropathy is investigational and has not been cleared or approved by the FDA.

MANAMED Receives Expanded 510(k) Clearance for ManaFlexx 2

Retrieved on: 
Thursday, November 16, 2023
Transcutaneous electrical nerve stimulation, Arm, Chronic pain, TENS, EMS, US Foods, Exercise, Shoulder, FDA, Arthritis, System, Neurostimulation, Pain, NMES, Athlete, Leg, Skin, Poultry farming

DENTON, Texas, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC. ManaFlexx 2 is a compact medical device that delivers electrical pulses to the user's skin through the company's patented wireless technology for two distinct uses. The expanded indication applies to both ManaFlexx 2 device's indications: Neuromuscular Electrical Stimulation (NMES) and Transcutaneous Electrical Nerve Stimulation (TENS).

Key Points: 
  • DENTON, Texas, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC.
  • ManaFlexx 2 is a compact medical device that delivers electrical pulses to the user's skin through the company's patented wireless technology for two distinct uses.
  • The expanded indication applies to both ManaFlexx 2 device's indications: Neuromuscular Electrical Stimulation (NMES) and Transcutaneous Electrical Nerve Stimulation (TENS).
  • This expanded indication joins the previous FDA clearance granted for the noninvasive device as an adjunctive treatment in the management of post-surgical and post- traumatic acute pain.

Vagus nerve stimulation reduces inflammation in children with Inflammatory Bowel Disease, Feinstein Institutes study finds

Retrieved on: 
Wednesday, October 18, 2023
Research, Managed Care, General Health, Consumer, Medical Devices, Children, Science, Biotechnology, Neurology, Practice Management, Other Science, Health, Abdominal pain, Child, MRI, Medical research, Feinstein, Inflammation, Feinstein Institutes for Medical Research, Cohen, FC, Vagus nerve, Weatherall Institute of Molecular Medicine, Heart rate, Diarrhea, Human, Medicine, Prevalence, Vagus nerve stimulation, Incontinence, Diabetes, Rheumatoid arthritis, MBA, Electricity, TENS, Bleeding, GE Research, Ulcerative colitis, Multimedia, Northwell Health, Disease, Clinical trial, Nature Communications, Pulmonary hypertension, Neuroscience, Ear, Arthritis, IBD, Sickle Cell Anemia, a Molecular Disease, Credit, Molecular medicine, Brain, Cancer, Patient, Liver disease, Biomedical engineering, Bangladesh Technical Education Board, MS, Central nervous system, Lupus, Medical imaging, Pharmaceutical industry, Management, Gastroenterology, MD

View the full release here: https://www.businesswire.com/news/home/20231018401966/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018401966/en/
    The Feinstein Institutes for Medical Research’s Dr. Benjamin Sahn led the vagus nerve stimulation clinical trial.
  • Inflammation and the inflammatory reflex – the neuronal signaling between the brain and body – is an important immune response.
  • Previous research and functional MRI studies have mapped stimulation of the auricular branch of the vagus nerve to activate the same brain regions as implanted devices, confirming this nerve as a suitable non-invasive target to administer vagus nerve stimulation.
  • Also, Feinstein Institutes researchers, in collaboration with GE Research, published research that harnessed ultrasound technology to reduce inflammation in the body non-invasively.

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

Retrieved on: 
Monday, October 2, 2023
Contraindication, TENS, Label, Partnership, Education, Sleep, Sale, National Fibromyalgia Association, Fibromyalgia, NFA, Chronic pain, Nursing, Dietary supplement

WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).

Key Points: 
  • WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).
  • As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for people living with fibromyalgia and their loved ones.
  • “We are delighted to work with the National Fibromyalgia Association to further our mutual commitment to the fibromyalgia community,” said Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix.
  • The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109.

Comprehensive Report on Electrical Muscle Stimulation Market 2024-2034 Reveals Emerging Trends and Key Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Medical Devices, TENS, FES, Rehabilitation, NMES, SWOT, SWOT analysis, Pain management, Growth & Opportunity Project, R, D, Medical device, Retail

The "The Global Electrical Muscle Stimulation Market 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Electrical Muscle Stimulation Market 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • The recently released report titled "The Global Electrical Muscle Stimulation Market 2024-2034" presents a comprehensive analysis of the global muscle stimulator devices market.
  • It offers a deep dive into market size, growth trends, emerging technologies, regulatory landscape, competitive dynamics, and leading companies.
  • The report delves into various types of muscle stimulators, including transcutaneous electrical nerve stimulation (TENS) devices, neuromuscular electrical stimulators (NMES), functional electrical stimulation (FES), interferential current (IFC) devices, microcurrent stimulators, and more.